4D Molecular Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
4D Molecular Therapeutics, Inc. (FDMT) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.88 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.88M, a 18.68% increase year-over-year.
- 4D Molecular Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $4.45M, a 36.26% decline year-over-year.
- 4D Molecular Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $4.52M, a 30.37% decline year-over-year.
- 4D Molecular Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.96M, a 18.37% decline year-over-year.
- 4D Molecular Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $22.02M, a 15.70% decline from fiscal 2024.
- 4D Molecular Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $26.12M, a 32.80% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $19.66M, a 14.86% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $17.12M, a 24.07% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.88M 10-Q · filed 2026-08-13 | $10.34M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $4.45M 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $22.02M 10-K · filed 2026-03-18 | |||
| 2025-09-30 | $4.52M 10-Q · filed 2025-11-10 | $9.48M derived: sum of 2 quarters · filed 2026-08-13 | $16.46M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $4.96M 10-Q · filed 2026-08-13 | $11.94M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $6.99M 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $26.12M 10-K · filed 2026-03-18 | |||
| 2024-09-30 | $6.49M 10-Q · filed 2025-11-10 | $12.56M derived: sum of 2 quarters · filed 2025-11-10 | $18.54M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $6.07M 10-Q · filed 2025-11-10 | $12.05M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $5.97M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $19.66M 10-K · filed 2025-02-28 | |||
| 2023-09-30 | $4.56M 10-Q · filed 2024-11-13 | $9.53M derived: sum of 2 quarters · filed 2024-11-13 | $13.75M derived: sum of 3 quarters · filed 2024-11-13 | |
| 2023-06-30 | $4.97M 10-Q · filed 2024-11-13 | $9.19M derived: sum of 2 quarters · filed 2024-11-13 | ||
| 2023-03-31 | $4.22M 10-Q · filed 2024-11-13 | |||
| 2022-12-31 | $17.12M 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $4.52M 10-Q · filed 2023-11-09 | $8.84M derived: sum of 2 quarters · filed 2023-11-09 | $12.78M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $4.32M 10-Q · filed 2023-11-09 | $8.26M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $3.93M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $13.80M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $3.92M 10-Q · filed 2022-11-08 | $7.74M derived: sum of 2 quarters · filed 2022-11-08 | $10.07M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $3.82M 10-Q · filed 2022-11-08 | $6.14M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $2.33M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $4.98M 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $1.15M 10-Q · filed 2021-11-10 | $2.18M derived: sum of 2 quarters · filed 2021-11-10 | $3.27M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $1.04M 10-Q · filed 2021-11-10 | $2.12M derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $1.08M 10-Q · filed 2021-11-10 | |||
| 2019-12-31 | $3.54M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |